Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Depreciation and Depletion (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Depreciation and Depletion for 16 consecutive years, with $425000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion fell 2.75% to $425000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 5.31% increase, with the full-year FY2024 number at $1.7 million, up 17.24% from a year prior.
  • Depreciation and Depletion was $425000.0 for Q3 2025 at Harvard Bioscience, up from $411000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $470000.0 in Q4 2021 to a low of $331000.0 in Q4 2022.
  • A 5-year average of $406368.4 and a median of $418000.0 in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: fell 29.57% in 2022, then increased 28.61% in 2024.
  • Harvard Bioscience's Depreciation and Depletion stood at $470000.0 in 2021, then fell by 29.57% to $331000.0 in 2022, then increased by 17.82% to $390000.0 in 2023, then rose by 17.69% to $459000.0 in 2024, then decreased by 7.41% to $425000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Depreciation and Depletion are $425000.0 (Q3 2025), $411000.0 (Q2 2025), and $451000.0 (Q1 2025).